First Trust Intermediate Durat (FPF) 23.55 $FPF First

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
First Trust Intermediate Durat (FPF) 23.55 $FPF

First Trust Intermediate Duration Preferred & Income Fund Declares its Monthly Common Share Distribution of $0.1625 Per Share for July
BusinessWire - Mon Jun 20, 3:31PM CDT
First Trust Intermediate Duration Preferred & Income Fund (the "Fund" (NYSE: FPF) has declared the Fund's regularly scheduled monthly common share distribution in the amount of $0.1625 per share payable on July 15, 2016, to shareholders of record as of July 6, 2016. The ex-dividend date is expected to be July 1, 2016. The monthly distribution information for the Fund appears below.
FPF: 23.55 (-0.05)

First Trust Intermediate Duration Preferred & Income Fund Declares its Monthly Common Share Distribution of $0.1625 Per Share for May
BusinessWire - Wed Apr 20, 3:49PM CDT
First Trust Intermediate Duration Preferred & Income Fund (the "Fund" (NYSE: FPF) has declared the Fund's regularly scheduled monthly common share distribution in the amount of $0.1625 per share payable on May 16, 2016, to shareholders of record as of May 4, 2016. The ex-dividend date is expected to be May 2, 2016. The monthly distribution information for the Fund appears below.
FPF: 23.55 (-0.05)

First Trust Intermediate Duration Preferred & Income Fund Declares its Monthly Common Share Distribution of $0.1625 Per Share for April
BusinessWire - Mon Mar 21, 3:56PM CDT
First Trust Intermediate Duration Preferred & Income Fund (the "Fund" (NYSE: FPF) has declared the Fund's regularly scheduled monthly common share distribution in the amount of $0.1625 per share payable on April 15, 2016, to shareholders of record as of April 5, 2016. The ex-dividend date is expected to be April 1, 2016. The monthly distribution information for the Fund appears below.
FPF: 23.55 (-0.05)

First Trust Advisors L.P. Announces Portfolio Manager Conference Call for First Trust Intermediate Duration Preferred & Income Fund
BusinessWire - Thu Feb 04, 3:14PM CST
First Trust Advisors L.P. ("FTA" announced today that First Trust Intermediate Duration Preferred & Income Fund (NYSE: FPF) (the "Fund" intends to host a conference call with Stonebridge Advisors LLC ("Stonebridge", the Fund's investment sub-advisor, on Thursday, February 18, 2016, at 4:15 P.M. Eastern Time. The purpose of the call is to hear the Fund's portfolio management team provide an update for the Fund.
FPF: 23.55 (-0.05)

First Trust Intermediate Duration Preferred & Income Fund announces distribution of USD0.1625 per share for February
M2 - Thu Jan 21, 5:50AM CST
First Trust Intermediate Duration Preferred & Income Fund (NYSE:FPF) reported on Thursday that it will pay a scheduled monthly common share distribution of USD0.1625 per share.
FPF: 23.55 (-0.05)

First Trust Intermediate Duration Preferred & Income Fund Declares its Monthly Common Share Distribution of $0.1625 Per Share for February
BusinessWire - Wed Jan 20, 4:33PM CST
First Trust Intermediate Duration Preferred & Income Fund (the "Fund" (NYSE: FPF) has declared the Fund's regularly scheduled monthly common share distribution in the amount of $0.1625 per share payable on February 16, 2016, to shareholders of record as of February 3, 2016. The ex-dividend date is expected to be February 1, 2016. The monthly distribution information for the Fund appears below.
FPF: 23.55 (-0.05)

First Trust Intermediate Duration Preferred & Income Fund announces USD0.1625 per share distribution for January
M2 - Tue Dec 22, 5:51AM CST
First Trust Intermediate Duration Preferred & Income Fund (NYSE:FPF) disclosed on Tuesday that it will pay a regular scheduled monthly common share distribution of USD0.1625 per share.
FPF: 23.55 (-0.05)

First Trust Intermediate Duration Preferred & Income Fund Declares its Monthly Common Share Distribution of $0.1625 Per Share for January
BusinessWire - Mon Dec 21, 3:54PM CST
First Trust Intermediate Duration Preferred & Income Fund (the "Fund" (NYSE: FPF) has declared the Fund's regularly scheduled monthly common share distribution in the amount of $0.1625 per share payable on January 15, 2016, to shareholders of record as of January 6, 2016. The ex-dividend date is expected to be January 4, 2016. The monthly distribution information for the Fund appears below.
FPF: 23.55 (-0.05)

First Trust Intermediate Duration Preferred & Income Fund Declares its Monthly Common Share Distribution of $0.1625 Per Share for December
BusinessWire - Thu Nov 19, 3:38PM CST
First Trust Intermediate Duration Preferred & Income Fund (the "Fund" (NYSE: FPF) has declared the Fund's regularly scheduled monthly common share distribution in the amount of $0.1625 per share payable on December 10, 2015, to shareholders of record as of December 3, 2015. The ex-dividend date is expected to be December 1, 2015. The monthly distribution information for the Fund appears below.
FPF: 23.55 (-0.05)

First Trust Intermediate Duration Preferred & Income Fund Declares its Monthly Common Share Distribution of $0.1625 Per Share for November
BusinessWire - Tue Oct 20, 3:46PM CDT
First Trust Intermediate Duration Preferred & Income Fund (the "Fund" (NYSE: FPF) has declared the Fund's regularly scheduled monthly common share distribution in the amount of $0.1625 per share payable on November 16, 2015, to shareholders of record as of November 4, 2015. The ex-dividend date is expected to be November 2, 2015. The monthly distribution information for the Fund appears below.
FPF: 23.55 (-0.05)

First Trust Intermediate Duration Preferred & Income Fund Declares its Monthly Common Share Distribution of $0.1625 Per Share for October
BusinessWire - Mon Sep 21, 3:23PM CDT
First Trust Intermediate Duration Preferred & Income Fund (the "Fund" (NYSE: FPF) has declared the Fund's regularly scheduled monthly common share distribution in the amount of $0.1625 per share payable on October 15, 2015, to shareholders of record as of October 5, 2015. The ex-dividend date is expected to be October 1, 2015. The monthly distribution information for the Fund appears below.
FPF: 23.55 (-0.05)

First Trust Intermediate Duration Preferred & Income Fund announces distribution of USD0.1625 per share for September
M2 - Fri Aug 21, 5:00AM CDT
First Trust Intermediate Duration Preferred & Income Fund (NYSE:FPF) announced on Friday that it will pay a monthly regular common share distribution pf USD0.1625 per share.
FPF: 23.55 (-0.05)

First Trust Intermediate Duration Preferred & Income Fund Declares its Monthly Common Share Distribution of $0.1625 Per Share for September
BusinessWire - Thu Aug 20, 3:42PM CDT
First Trust Intermediate Duration Preferred & Income Fund (the "Fund" (NYSE: FPF) has declared the Fund's regularly scheduled monthly common share distribution in the amount of $0.1625 per share payable on September 15, 2015, to shareholders of record as of September 3, 2015. The ex-dividend date is expected to be September 1, 2015. The monthly distribution information for the Fund appears below.
FPF: 23.55 (-0.05)

First Trust Intermediate Duration Preferred & Income Fund Declares its Monthly Common Share Distribution of $0.1625 Per Share for August
BusinessWire - Mon Jul 20, 4:23PM CDT
First Trust Intermediate Duration Preferred & Income Fund (the "Fund" (NYSE: FPF) has declared the Fund's regularly scheduled monthly common share distribution in the amount of $0.1625 per share payable on August 17, 2015, to shareholders of record as of August 5, 2015. The ex-dividend date is expected to be August 3, 2015. The monthly distribution information for the Fund appears below.
FPF: 23.55 (-0.05)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading